What's Happening?
The 10th Tumor Models Summit in San Francisco is bringing together industry leaders and vendors to explore advancements in tumor modeling. As the FDA phases out animal testing requirements, the summit
focuses on innovative modalities like ADCs, bispecifics, and T-cell engagers. The event aims to accelerate patient-derived model development using CRISPR and AI technologies, positioning pipelines ahead of the curve.
Why It's Important?
This summit reflects the ongoing transformation in oncology research, driven by regulatory changes and technological advancements. The shift towards more predictive models can enhance drug development processes and improve treatment outcomes. Industry stakeholders have the opportunity to network and collaborate, potentially leading to breakthroughs in cancer research and therapy.
What's Next?
Participants may leverage insights from the summit to refine their model selection strategies and optimize their research pipelines. The event could lead to new partnerships and collaborations, fostering innovation in the oncology field. As the industry adapts to regulatory changes, stakeholders will likely focus on integrating advanced technologies into their research and development efforts.
